Menopur (Menotrophin)

Menotropin contains both follicle‑stimulating hormone (FSH) and luteinizing hormone (LH) isoforms. It binds to FSH receptors on granulosa cells and LH receptors on theca cells, promoting follicle growth, estrogen synthesis, and final maturation that leads to ovulation.

The dose of Menopur is individualized by the prescribing clinician based on the patient’s ovarian response, age, body weight, and treatment protocol. The prescriber determines the number of international units (IU) per injection and the overall treatment schedule.

Menopur is intended for use before conception to induce ovulation; it is not administered during an established pregnancy. Safety data for use in pregnancy or while breastfeeding are limited, and the product should be avoided in these situations unless specifically directed by a qualified healthcare professional.

To place an order, submit an enquiry on the Menopur product page at gnhindia.com, providing the required quantity and institutional credentials. GNH India works with hospitals, pharmacies and procurement teams worldwide, confirming trade or institutional verification before supplying pricing, availability, cold‑chain shipping details and necessary import documentation.

Menopur provides both FSH and LH activity in a single preparation, whereas some alternatives such as recombinant FSH contain only FSH and require separate LH supplementation. This combined profile can simplify dosing regimens, but individual response, cost considerations and specific protocol requirements may influence the choice of therapy.

Menopur must be stored refrigerated at 2‑8 °C (36‑46 °F). Keep the vial in its original carton, protect it from light, and do not freeze or shake the solution. Once reconstituted, use within the time frame specified in the product labeling and retain refrigeration.

Menopur is supplied as a sterile injection solution for subcutaneous use. The prescribed dose is drawn into a syringe and injected into the subcutaneous tissue of the abdomen or thigh, typically once daily, following the schedule defined by the fertility specialist.

The most serious risks include ovarian hyperstimulation syndrome (OHSS), which can cause abdominal pain, rapid weight gain, and fluid accumulation, and the possibility of multiple pregnancy. Severe allergic reactions and rare thromboembolic events are also critical concerns that require immediate medical attention.

Menopur is contraindicated in women with known hypersensitivity to menotropin or any component of the formulation, uncontrolled thyroid disease, active ovarian cysts, or severe ovarian failure. It should also be avoided in patients with a history of severe OHSS or those who are currently pregnant.